MX2021002884A - Terapia de combinacion para el tratamiento de cancer de prostata. - Google Patents
Terapia de combinacion para el tratamiento de cancer de prostata.Info
- Publication number
- MX2021002884A MX2021002884A MX2021002884A MX2021002884A MX2021002884A MX 2021002884 A MX2021002884 A MX 2021002884A MX 2021002884 A MX2021002884 A MX 2021002884A MX 2021002884 A MX2021002884 A MX 2021002884A MX 2021002884 A MX2021002884 A MX 2021002884A
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- treatment
- combination therapy
- combination
- faromadomain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730869P | 2018-09-13 | 2018-09-13 | |
| US201862737612P | 2018-09-27 | 2018-09-27 | |
| US201862778185P | 2018-12-11 | 2018-12-11 | |
| PCT/US2019/050970 WO2020056232A1 (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002884A true MX2021002884A (es) | 2021-07-15 |
Family
ID=69778254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002884A MX2021002884A (es) | 2018-09-13 | 2019-09-13 | Terapia de combinacion para el tratamiento de cancer de prostata. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220117942A1 (https=) |
| EP (1) | EP3849544A4 (https=) |
| JP (1) | JP7441214B2 (https=) |
| KR (1) | KR102844523B1 (https=) |
| CN (1) | CN112912075B (https=) |
| AU (1) | AU2019338483B2 (https=) |
| CA (1) | CA3112396A1 (https=) |
| IL (1) | IL281281B2 (https=) |
| MX (1) | MX2021002884A (https=) |
| SG (1) | SG11202102492PA (https=) |
| TW (1) | TWI816880B (https=) |
| WO (1) | WO2020056232A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
| US20220265618A1 (en) * | 2021-02-22 | 2022-08-25 | Celgene Quanticel Research, Inc. | Methods of treating prostate cancer |
| CN114644687B (zh) * | 2022-04-07 | 2023-06-27 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP2621483A1 (en) * | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| CA2915838C (en) * | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| WO2015065919A1 (en) * | 2013-10-28 | 2015-05-07 | The Regents Of The University Of California | Treatment of metastatic prostate cancer |
| NO2719005T3 (https=) * | 2014-07-28 | 2018-01-20 | ||
| WO2016171470A1 (en) * | 2015-04-21 | 2016-10-27 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and methods to prevent or treat a cancer |
| WO2017216772A2 (en) * | 2016-06-16 | 2017-12-21 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| WO2018106433A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent |
-
2019
- 2019-09-12 TW TW108133128A patent/TWI816880B/zh active
- 2019-09-13 EP EP19860912.5A patent/EP3849544A4/en active Pending
- 2019-09-13 WO PCT/US2019/050970 patent/WO2020056232A1/en not_active Ceased
- 2019-09-13 JP JP2021514070A patent/JP7441214B2/ja active Active
- 2019-09-13 MX MX2021002884A patent/MX2021002884A/es unknown
- 2019-09-13 IL IL281281A patent/IL281281B2/en unknown
- 2019-09-13 AU AU2019338483A patent/AU2019338483B2/en active Active
- 2019-09-13 CA CA3112396A patent/CA3112396A1/en active Pending
- 2019-09-13 CN CN201980059904.2A patent/CN112912075B/zh active Active
- 2019-09-13 KR KR1020217010491A patent/KR102844523B1/ko active Active
- 2019-09-13 SG SG11202102492PA patent/SG11202102492PA/en unknown
- 2019-09-13 US US17/275,473 patent/US20220117942A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019338483A1 (en) | 2021-04-08 |
| IL281281B1 (en) | 2025-11-01 |
| JP7441214B2 (ja) | 2024-02-29 |
| JP2022500431A (ja) | 2022-01-04 |
| KR20210060515A (ko) | 2021-05-26 |
| EP3849544A1 (en) | 2021-07-21 |
| AU2019338483B2 (en) | 2025-01-02 |
| TWI816880B (zh) | 2023-10-01 |
| EP3849544A4 (en) | 2022-06-08 |
| CA3112396A1 (en) | 2020-03-19 |
| SG11202102492PA (en) | 2021-04-29 |
| CN112912075B (zh) | 2023-04-04 |
| US20220117942A1 (en) | 2022-04-21 |
| IL281281B2 (en) | 2026-03-01 |
| KR102844523B1 (ko) | 2025-08-12 |
| TW202017926A (zh) | 2020-05-16 |
| CN112912075A (zh) | 2021-06-04 |
| WO2020056232A1 (en) | 2020-03-19 |
| IL281281A (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202501583B (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX379621B (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX2017005929A (es) | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. | |
| MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| ZA201607488B (en) | Compounds for treating brain cancer | |
| MX2015014591A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. | |
| MX2017015896A (es) | Agente anticancerigeno. | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| HK1258319A1 (zh) | 癌症疗法 | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| MY176599A (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. |